Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Account Payables: 2012-2017

Historic Change in Account Payables for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Dec 2017 value amounting to -$1.1 million.

  • Rocket Pharmaceuticals' Change in Account Payables rose 136.76% to $68,000 in Q4 2017 from the same period last year, while for Dec 2017 it was -$1.1 million, marking a year-over-year decrease of 2682.93%. This contributed to the annual value of -$1.1 million for FY2017, which is 2682.93% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Change in Account Payables of -$1.1 million as of FY2017, which was down 2,682.93% from -$41,000 recorded in FY2016.
  • Rocket Pharmaceuticals' 5-year Change in Account Payables high stood at $917,000 for FY2014, and its period low was -$1.1 million during FY2017.
  • For the 3-year period, Rocket Pharmaceuticals' Change in Account Payables averaged around -$231,667, with its median value being -$41,000 (2016).
  • Per our database at Business Quant, Rocket Pharmaceuticals' Change in Account Payables skyrocketed by 680.38% in 2014 and then crashed by 2,682.93% in 2017.
  • Over the past 5 years, Rocket Pharmaceuticals' Change in Account Payables (Yearly) stood at -$158,000 in 2013, then spiked by 680.38% to $917,000 in 2014, then slumped by 46.89% to $487,000 in 2015, then crashed by 108.42% to -$41,000 in 2016, then plummeted by 2,682.93% to -$1.1 million in 2017.